Clinical trial
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When…
NCT00436007 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00436007 |
|---|---|
| Title | Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen |
| Official title | Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Biological |
| Interventions | GSK 257049, Tritanrix™ HepB/Hib, Rouvax™, Stamaril™, Polio Sabin™ |
| Enrollment | 511 |
| Start date | Apr 30, 2007 |
| Primary completion | Sep 15, 2008 |
| Completion | Oct 7, 2009 |
| First posted | Feb 16, 2007 |
| Last update posted | Aug 16, 2018 |
| Countries | Gabon, Ghana, Tanzania |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: